lisocabtagene maraleucel
bms
['lymsm', 'liso-cel']
#eha2022 | , , showed that liso-cel as second-line treatment in patients with lbcl who met 1 frailty criteria and for whom hsct was not intended led to durable responses (median pfs and os, nr; 6-mo pfs for hl pts, 75%) &amp; no new safety concerns #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm